Taysha Gene Therapies (TSHA) Non-Current Deffered Revenue (2023)
Taysha Gene Therapies (TSHA) reported Non-Current Deffered Revenue of $3.0 million for Q3 2023, down 51.61% sequentially from $6.2 million in Q2 2023.
Taysha Gene Therapies (TSHA) Non-Current Deffered Revenue (2023) Analysis & Trends
Taysha Gene Therapies (TSHA) has 1 years of Non-Current Deffered Revenue data on file, last reported at $3.0 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Taysha Gene Therapies | 2.14 Bn | 2.14 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 3.00 Mn |
| Jun 30, 2023 | 6.20 Mn |